| Factor Information | |
|---|---|
| Data ID | 829 |
| Factor | BNP(pg/ml) |
| Description | Some biomarkers play important roles in the endothelial dysfunction of patients with pulmonary arterial hypertension (PAH), including nitric oxide (NO), endothelin-1 (ET-1), asymmetric dimethylarginine (ADMA), galectin-3 (Gal-5), B-type natriuretic peptide (BNP), and uric acid. |
| Biomarker | YES |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | treatment and prognosis |
| Objective | This study aimed at selecting effective biomarkers that could be used to assess the severity of CHD–PAH in patients and investigating the effect of iloprost at the level of biomarkers. |
| p Value | <0.05 |
| Conclusion | A significant positive linear relationship was observed between mPAP and plasma ET-1, BNP, ADMA, and uric acid levels in all patients with CHD-PAH. ET-2, ADMA, BNP, and UA levels had a significant linear relationship with mean pulmonary arterial pressure, which could be used to predict the severity of CHD-PAH. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 484 |
| CHD Type | isolated CHD |
| CHD Subtype | ASD/VSD/PDA |
| Reference | |
|---|---|
| PMID | 28608969 |
| Year | 2017 |
| Title | Effect of iloprost on biomarkers in patients with congenital heart disease-pulmonary arterial hypertension. |
| Sample | ||
|---|---|---|
| Population | patients with CHD-PAH | |
| Source | blood | |
| Region | Shanghi, China | |
| Method | This prospective and observational study enrolled patients with CHD‐PAH. | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | iloprost negative group [ING](Treatment) | iloprost positive group [IPG](Control) |
| Number | 19 | 7 |
| Age | ING:49.52±14.43 years | IPG:48.57±12.56 years |
| Gender (Male: Female) | 5:14 | 0:7 |
| Marker Level | 1687.67±1876.10 | 529.36±411.69 |
